Goldman Sachs Group set a €77.00 ($89.53) price target on Bayer (FRA:BAYN) in a research report released on Tuesday, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.
BAYN has been the topic of a number of other research reports. Kepler Capital Markets set a €70.00 ($81.40) target price on Bayer and gave the company a neutral rating in a report on Monday, March 25th. JPMorgan Chase & Co. set a €70.00 ($81.40) target price on Bayer and gave the company a neutral rating in a report on Thursday, March 28th. UBS Group set a €110.00 ($127.91) target price on Bayer and gave the company a buy rating in a report on Thursday, March 28th. Deutsche Bank set a €70.00 ($81.40) target price on Bayer and gave the company a neutral rating in a report on Monday, April 1st. Finally, DZ Bank reissued a neutral rating on shares of Bayer in a report on Tuesday, April 2nd. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of €81.67 ($94.97).
Shares of FRA BAYN opened at €56.95 ($66.22) on Tuesday. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.